Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.34 |
| ▸ | GPR6 | P46095 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.31 |
| ▸ | CTSD | P07339 | 2/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5041306 | 0.86 | MAPK8 (0.42) | F10EPHX2DGAT2MAPK8MAPK9 | |
| SCHEMBL5040465 | 0.86 | DGAT2 (0.38) | F10EPHX2DGAT2MAPK8MAPK9 | |
| SCHEMBL5040473 | 0.86 | DGAT2 (0.38) | F10EPHX2DGAT2MAPK8MAPK9 | |
| SCHEMBL5037335 | 0.85 | MAPK8 (0.40) | F10DGAT2MAPK8MAPK9MAPK10 | |
| SCHEMBL5037337 | 0.85 | MAPK8 (0.40) | F10DGAT2MAPK8MAPK9MAPK10 | |
| Hydrochloric Acid SCHEMBL5045204 | 0.85 | F10 (0.46) | F10EPHX2CARM1PRMT6CHRM4 | |
| SCHEMBL5042085 | 0.85 | P2RX7 (0.41) | EPHX2DGAT2MAPK8MAPK9MAPK10 | |
| SCHEMBL5042078 | 0.85 | P2RX7 (0.41) | EPHX2DGAT2MAPK8MAPK9MAPK10 | |
| SCHEMBL5045413 | 0.83 | SMN1; SMN2 (0.38) | EPHX2DGAT2MAPK8MAPK9MAPK10 | |
| SCHEMBL5041946 | 0.82 | DGAT2 (0.42) | DGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | F10 8/4885EPHX2 1557/4885DGAT2 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.